Membranous Nephropathy Associated with the Relatively Selective Cyclooxygenase-2 Inhibitor, Etodolac, in a Patient with Early Rheumatoid Arthritis

Toshiro Sugimoto, Masahiro Aoyama, Katsuhisa Kikuchi, Masayoshi Sakaguchi, Naoko Deji, Takashi Uzu, Yoshihiko Nishio, Atsunori Kashiwagi

Internal Medicine · 2007 · 12 citations · 10 references

DOIFull text

Open access

Concepts

Abstract

Renal dysfunction and urinary abnormalities, which are usually related to drug toxicity, secondary amyloidosis, or those which overlap with other autoimmune conditions, are frequently observed in patients with rheumatoid arthritis. This is the first case report of membranous nephropathy in a patient with early-stage rheumatoid arthritis treated with the relatively selective cyclooxygenase-2 inhibitor, etodolac. The present case suggests that any kind of non-steroidal anti-inflammatory drug can cause membranous nephropathy; thus, physicians should be aware of this renal toxicity when prescribing these drugs.

References

10